Ironwood Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) saw some unusual options trading on Monday. Stock traders acquired 3,553 call options on the stock. This represents an increase of 1,479% compared to the typical daily volume of 225 call options.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD traded down $0.06 during midday trading on Monday, reaching $1.86. 2,936,392 shares of the company’s stock traded hands, compared to its average volume of 2,475,660. The company has a market cap of $302.13 million, a price-to-earnings ratio of -37.19 and a beta of 0.30. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $5.13. The stock has a 50 day moving average of $1.42 and a 200 day moving average of $1.00.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.16. The firm had revenue of $85.24 million for the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts predict that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Institutional Trading of Ironwood Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC increased its position in Ironwood Pharmaceuticals by 43.5% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 72,706 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 22,029 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Ironwood Pharmaceuticals by 23.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 154,388 shares of the biotechnology company’s stock worth $202,000 after buying an additional 28,928 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth about $48,000. Merit Financial Group LLC increased its position in Ironwood Pharmaceuticals by 17.4% in the third quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock worth $64,000 after buying an additional 7,232 shares in the last quarter. Finally, CWM LLC increased its position in Ironwood Pharmaceuticals by 27.4% in the third quarter. CWM LLC now owns 232,790 shares of the biotechnology company’s stock worth $305,000 after buying an additional 50,016 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have commented on IRWD. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Zacks Research upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $4.94.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.